Evidence map›Paper›PMID 42155650›Full record

ArticleJournal of substance use and addiction treatment2026

"We need to keep in mind that battle fatigue": A commentary on moral injury among substance use treatment and community service providers.

Elizabeth C Saunders, Bethany McLeman, Lisa A Marsch, Sarah K Moore, Brittney Ackerson, Amanda Cowan, Shauna M Filion, Ryan Fowler, Lindsay Fox, John Gary and 17 more

Abstract read
In one paragraph

Article in Journal of substance use and addiction treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Elizabeth C SaundersNortheast Node of the National Drug Abuse Treatment Clinical Trials Network, Center for Technology and Behavioral Health, Geisel School of Medicine at Dartmouth, 46 Centerra Pkwy, Suite 315, NH, 03766, Lebanon. Electronic address: Elizabeth.C.Saunders@dartmouth.edu.
Bethany McLemanNortheast Node of the National Drug Abuse Treatment Clinical Trials Network, Center for Technology and Behavioral Health, Geisel School of Medicine at Dartmouth, 46 Centerra Pkwy, Suite 315, NH, 03766, Lebanon. Electronic address: Bethany.M.McLeman@dartmouth.edu.
Lisa A MarschNortheast Node of the National Drug Abuse Treatment Clinical Trials Network, Center for Technology and Behavioral Health, Geisel School of Medicine at Dartmouth, 46 Centerra Pkwy, Suite 315, NH, 03766, Lebanon. Electronic address: Lisa.A.Marsch@dartmouth.edu.
Sarah K MooreNortheast Node of the National Drug Abuse Treatment Clinical Trials Network, Center for Technology and Behavioral Health, Geisel School of Medicine at Dartmouth, 46 Centerra Pkwy, Suite 315, NH, 03766, Lebanon. Electronic address: sarah.k.moore@dartmouth.edu.
Brittney AckersonCorazon Day Center, San Antonio, TX 78215, United States of America. Electronic address: brittney@corazonsa.org.
Amanda CowanCommunity Health Project Los Angeles, Los Angeles, CA, 90029, United States of America.
Shauna M FilionUniversity of Utah Medical Center, Salt Lake City, UT, 84132, United States of America. Electronic address: u0920272@utah.edu.
Ryan FowlerHIV/HCV Resource Center, NH, 03766, Lebanon. Electronic address: RFowler@h2rc.org.
Lindsay FoxCenter for Inclusive Health at the University of New Mexico, Albuquerque, NM, 87131, United States of America. Electronic address: lefox@salud.unm.edu.
John GaryGibson Center for Behavioral Change, Cape Girardeau, MO, 63703, United States of America. Electronic address: garyj@gibsonrecovery.org.
John HamiltonLiberation Programs, Inc., Bridgeport, CT, 06604, United States of America. Electronic address: john.hamilton@liberationprograms.org.
Rich JonesYouturn Health, Greenville, SC, 29607, United States of America. Electronic address: rjones@youturnhealth.com.
Ayana JordanNew York University Grossman School of Medicine, Department of Psychiatry, NY, NY, 10016, United States of America. Electronic address: Ayana.jordan@nyulangone.org.
Roxanne KibbenHennepin Healthcare Research Institute, Minneapolis, MN, 55404, United States of America.
Malika LamontVOCAL-WA and LEAD-WA, Seattle, WA, United States of America.
Tricia LawdahlFaces and Voices of Recovery, Upstate South Carolina, Greenville, SC, United States of America. Electronic address: Tricia@favorupstate.org.
Jay PeeMinnesota Hope Dealerz Organization, Minneapolis, MN 55412, United States of America. Electronic address: jaypee@minnesotahopedealerz.org.
Jennifer PotterUniversity of Texas, San Antonio, San Antonio, TX, 78229, United States of America. Electronic address: potterjs@uthscsa.edu.
Michelle PeavyElson S. Floyd College of Medicine, Washington State University, Spokane, WA, 99202, United States of America. Electronic address: m.peavy@wsu.edu.
Thekla B RossConsultant to the Health Systems Node of the Clinical Trials Network, Clinical Psychologist, Strategic Advisor to NIAAA and Tech Companies, Self-Compassion Faculty, United States of America. Electronic address: theklabrumder@gmail.com.
David ScottUniversity of Pittsburgh Center for Research on Health Care, Pittsburgh, PA, 15213, United States of America. Electronic address: DAS348@pitt.edu.
Edward SuarezDepartment of Psychiatry, University of Miami Miller School of Medicine, Miami, FL, 33136, United States of America. Electronic address: exs1122@med.miami.edu.
Noel VestDepartment of Community Health Sciences, Boston University School of Public Health, Boston, MA, 02118, United States of America. Electronic address: vest@bu.edu.
Hoa VoNational Institute on Drug Abuse, Bethesda, MD, United States of America.
Quandra BlackeneyNational Institute on Drug Abuse, Bethesda, MD, United States of America.
Carmen RosaNational Institute on Drug Abuse, Bethesda, MD, United States of America.
Steven H ChapmanNortheast Node of the National Drug Abuse Treatment Clinical Trials Network, Center for Technology and Behavioral Health, Geisel School of Medicine at Dartmouth, 46 Centerra Pkwy, Suite 315, NH, 03766, Lebanon; Dartmouth-Hitchcock Clinic, One Medical Center Drive, NH 03765, Lebanon. Electronic address: Steven.H.Chapman@hitchcock.org.

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
Project-004UG1DA020024 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI Steven J Shoptaw, MADHUKAR H. TRIVEDI · 2015 to 2026
$71.6M
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials NetworkUG1DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel J Feaster, Viviana Elizabeth Horigian · 2015 to 2026
$50.6M
The Ohio Valley Node of the Clinical Trials Network (CTN-0153)UG1DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI T John WINHUSEN · 2015 to 2026
$42.5M
Suicide Prediction and Prevention for People at Risk for Opioid Use DisorderUG1DA040316 · NIDA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI GAVIN BART · 2015 to 2026
$42.2M
Project-002UG1DA040309 · NIDA · DARTMOUTH COLLEGE · PI Lisa A. Marsch · 2015 to 2026
$37.9M
Project-002UG1DA040314 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Ingrid A Binswanger, CYNTHIA I CAMPBELL · 2015 to 2026
$34.9M
Southern Consortium Node of the Clinical Trials Network (Varenicline)UG1DA013727 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KATHLEEN T. BRADY, Kelly S. Barth · 2015 to 2026
$24.8M
Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6M
Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library)UG1DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI Mary Akiko Hatch, John M. Roll · 2015 to 2026
$19.8M
Greater Intermountain Node (CTN-0151)UG1DA049444 · NIDA · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Gerald T. Cochran, Adam Joseph Gordon · 2019 to 2026
$16.8M
NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA013714NIDA NIH HHS UG1 DA013720NIDA NIH HHS UG1 DA013727NIDA NIH HHS UG1 DA013732NIDA NIH HHS UG1 DA015815NIDA NIH HHS UG1 DA015831NIDA NIH HHS UG1 DA020024NIDA NIH HHS UG1 DA040309NIDA NIH HHS UG1 DA040314NIDA NIH HHS UG1 DA040316NIDA NIH HHS UG1 DA049435NIDA NIH HHS UG1 DA049436NIDA NIH HHS UG1 DA049444NIDA NIH HHS UG1 DA049467NIDA NIH HHS UG1 DA049468
6 · The paper itself

Abstract

introductionMoral injury is the psychological distress resulting from actions, or the lack thereof, which violate one's moral or ethical code. There is a notable gap in literature exploring moral injury among substance use disorder (SUD) treatment and community service providers. Despite the lack of literature describing moral injury among the SUD workforce, moral injury was discussed extensively during meetings of the Community Representative Council (CIRCL) of the National Drug Abuse Treatment Clinical Trials Network (CTN), which engages community members within the CTN Nodes to understand perspectives of people with lived/living experience and those providing substance use services.

methodsIn response to this consistently raised topic, this commentary reviews the literature on moral injury related to the SUD workforce, as well as the perspectives of CIRCL members on the unique and persistent challenges faced by SUD treatment and community services providers.

resultsMembers of CIRCL in the SUD treatment and community provider workforce consistently described experiencing morally injurious events, including acts of commission and omission, bearing witness, and observing betrayal from those in power. While some experiences are akin to those experienced by providers in other healthcare settings, some were unique to front-line SUD treatment and community services providers. These experiences caused intense experiences of guilt, isolation, and hopelessness, sometimes contributing to turnover.

conclusionsAddressing moral injury among the SUD provider workforce may require unique mitigation and prevention strategies, potentially involving structural changes at the organizational, social, and policy levels that support the SUD treatment and community service workforce, ultimately improving not just the wellbeing of providers and patients, but the wellbeing of our communities.

Indexed as

Community services providersMoral injurySubstance use disorder (SUD) treatment

Identifiers

PMID42155650
PMCPMC13426516

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.